Next Article in Journal
Synergistic In Vitro Antimicrobial Activity of Pomegranate Rind Extract and Zinc (II) against Micrococcus luteus under Planktonic and Biofilm Conditions
Next Article in Special Issue
Structure-Activity Relationships of Benzothiazole-Based Hsp90 C-Terminal-Domain Inhibitors
Previous Article in Journal
Model-Informed Optimization of a Pediatric Clinical Pharmacokinetic Trial of a New Spironolactone Liquid Formulation
Previous Article in Special Issue
Design and In Vitro Study of a Dual Drug-Loaded Delivery System Produced by Electrospinning for the Treatment of Acute Injuries of the Central Nervous System
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 13
Issue 6
10.3390/pharmaceutics13060850
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders

by
Payyalot Koyiparambath Vishal
1,
Jong Min Oh
2,
Ahmed Khames
3,
Mohamed A. Abdelgawad
4,5,
Aathira Sujathan Nair
1,
Lekshmi R. Nath
6,
Nicola Gambacorta
7,
Fulvio Ciriaco
8,
Orazio Nicolotti
7,
Hoon Kim
2,* and
Bijo Mathew
1,*
1
Department of Pharmaceutical Chemistry, AIMS Health Sciences Campus, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi 682041, India
2
Department of Pharmacy, Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Korea
3
Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Taif University, P.O. Box-11099, Taif 21944, Saudi Arabia
4
Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka 72341, Saudi Arabia
5
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni Suef 62514, Egypt
6
Department of Pharmacogonosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi 682041, India
7
Dipartimento di Farmacia—Scienze del Farmaco, Università degli Studi di Bari “Aldo Moro”, Via E. Orabona, 4, I-70125 Bari, Italy
8
Dipartimento di Chimica, Università degli Studi di Bari “Aldo Moro”, Via E. Orabona, 4, I-70125 Bari, Italy
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2021, 13(6), 850; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13060850
Submission received: 14 May 2021 / Revised: 2 June 2021 / Accepted: 5 June 2021 / Published: 8 June 2021
(This article belongs to the Special Issue Multi-Target Drug Design for Complex Diseases)
Browse Figures
Versions Notes

Abstract

:
Six halogenated trimethoxy chalcone derivatives (CH1–CH6) were synthesized and spectrally characterized. The compounds were further evaluated for their inhibitory potential against monoamine oxidases (MAOs) and β-secretase (BACE-1). Six compounds inhibited MAO-B more effectively than MAO-A, and the 2′,3′,4′-methoxy moiety in CH4–CH6 was more effective for MAO-B inhibition than the 2′,4′,6′-methoxy moiety in CH1–CH3. Compound CH5 most potently inhibited MAO-B, with an IC50 value of 0.46 µM, followed by CH4 (IC50 = 0.84 µM). In 2′,3′,4′-methoxy derivatives (CH4-CH6), the order of inhibition was –Br in CH5 > -Cl in CH4 > -F in CH6 at the para-position in ring B of chalcone. CH4 and CH5 were selective for MAO-B, with selectivity index (SI) values of 15.1 and 31.3, respectively, over MAO-A. CH4 and CH5 moderately inhibited BACE-1 with IC50 values of 13.6 and 19.8 µM, respectively. When CH4 and CH5 were assessed for their cell viability studies on the normal African Green Monkey kidney cell line (VERO) using MTT assays, it was noted that both compounds were found to be safe, and only a slightly toxic effect was observed in concentrations above 200 µg/mL. CH4 and CH5 decreased reactive oxygen species (ROS) levels of VERO cells treated with H2O2, indicating both compounds retained protective effects on the cells by antioxidant activities. All compounds showed high blood brain barrier permeabilities analyzed by a parallel artificial membrane permeability assay (PAMPA). Molecular docking and ADME prediction of the lead compounds provided more insights into the rationale behind the binding and the CNS drug likeness. From non-test mutagenicity and cardiotoxicity studies, CH4 and CH5 were non-mutagenic and non-/weak-cardiotoxic. These results suggest that CH4 and CH5 could be considered candidates for the cure of neurological dysfunctions.

1. Introduction

A well-known aspect of monoamine oxidases (MAOs) is their role in metabolizing various types of biogenic amines, which can impart a crucial role in modulating the central nervous system (CNS) neurotransmitter functions [1]. The malfunctioning of these neurotransmitters by the oxidative deamination process by MAOs leads to a variety of neurodegenerative disorders (NDDs) such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) [2,3,4]. Among the MAO family, selective inhibitors of MAO-A can be employed for managing various depressive states, and at the same time, inhibitors of MAO-B can be widely used for the adjuvant therapy for NDDs [5,6]
Subsequently, MAOs have been extensively researched, with over 23,000 publications dealing with their properties, enzymology, functions, and specific inhibitors from various classes, according to the PubMed database [7]. Monoamine oxidase was chosen as a target here since it is a common enzyme for various neurological disorders and has the benefit in kinetics studies of allowing us to determine how quickly enzymes will function in tissues with the substrate concentrations they are likely to encounter, as well as how different substrates will fight for the enzyme [8]. The life of two isoforms, MAO-A and MAO-B, each with distinct structural features, has inspired clinical strategies to develop isoform-tailored inhibitors that might be used to treat a wide range of depressive diseases and CNS-related disorders [9,10].
β-secretase (BACE-1) is a crucial cleaving enzyme that takes part in the degradation of the amyloid precursor protein (APP) [11]. This cleavage process leads to the formation of amyloid β (Aβ) protein, which is neurotoxic and can trigger the neurodegeneration and plaque deposition in the AD brain [12]. Numerous studies have documented that inhibitors of BACE-1 have a prominent role in diminishing the Aβ concentration in the brain and thwarting the progression of AD [13]. Considering the benefits of a multitarget directed ligand (MTDL) approach by inhibiting MAO-B and Aβ production would be of great interest in AD therapy. Very limited literature has been reported regarding the development of dual-acting MAO-B and BACE-1 inhibitors [14,15].
Chalcones are well-known structural motifs with α,β-unsaturated ketones and are open-chain flavonoids [16]. The presence of three rotatable bonds and the Michael acceptor nature of the linker present in the chalcone scaffold provided a remarkable ability to reach different enzyme targets [17]. Thus, many pharmacological active profiles involve chalcone-containing compounds, including anti-tumor, anti-diabetic, anti-inflammatory, and anti-AD agents [18,19,20,21,22]. Based upon the wealth of information, halogens have now established themselves as a central player in supramolecular chemistry with wide applications in medicinal chemistry [23]. The electron-accepting nature of halogens can preferably promote more non-covalent hydrophobic interactions in several enzyme targets [24]. A recent report documented that the presence of halogens in various classes of MAO inhibitors resulted in improved MAO-B selectivity by the stabilizing property of halogen bonding in the inhibitor-binding cavity (IBC) of the enzyme [25].
Based on the previous studies, in the simple framework of non-nitrogenous based chalcones, the selective and potent candidates against the MAO-B isoform were characterized by the presence of methoxyl or methyl substituents at the para or ortho positions of phenyl ring A [26,27,28,29,30,31]. At the same time, the presence of halogens and electron-releasing substituents, preferably methoxy, dimethylamino, ethyl acetohydroxamate, and ethoxy on the para position of phenyl ring B, are well tolerated in the MAO-B inhibition [32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50]. Based upon the existing literature, it is clearly proved that 99% of chalcone derived compounds are a selective and reversible type of MAO-B inhibitors [51,52,53]. In this scenario, our attention is mainly focused on the development of two series by the incorporation of three methoxy pharmacophores on the A ring of the phenyl ring of chalcones at the positions of 2′, 4′, and 6′ and 2′, 3′, and 4′, respectively. A variety of halogens such as chlorine, bromine, and fluorine have been also introduced on the para position on the B ring phenyl unit. To the best of our knowledge, such a design strategy has not been reported regarding the effect and orientation of various halogens and trimethoxyl groups on chalcones framework for the development of multi-targeted MAO-B/BACE-1 inhibitors.
The present study emphasizes the synthesis of 2′, 4′, and 6′ and 2′, 3′, and 4′ trimethoxylated halogenated chalcones and the evaluation of their MAO-A, MAO-B, and BACE-1 inhibition. The lead molecules were further studied in kinetics, reversibility, cytotoxicity, and reactive oxygen species (ROS) assays. A molecular docking study established the detailed protein–ligand binding interactions of the lead molecules in their respective active sites of enzyme targets.

2. Materials and Methods

2.1. Synthesis

A mixture of trimethoxy acetophenone (0.01 mol), para-substituted halogenated benzaldehyde (0.01 mol), and 50% KOH was added to 15 mL of methanol and was kept stirring at room temperature for 15 h [54]. The resulting solution was then filtered, washed with water, and dried. The product was then recrystallized from methanol-yielded pure crystals. The synthetic route for the titled derivatives is depicted in Scheme 1.

2.1.1. (E)-3-(4-chlorophenyl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one (CH1)

M.P: 136–138 °C; 1H NMR (500 MHz, CDCl3) δ: 3.77 (s, 6H, Ar-2′OCH3, Ar-6′OCH3,), 3.86 (s, 3H, Ar-4′OCH3), 6.15 (s, 2H, Ar-3′CH, Ar-5′CH), 6.94–6.91 (1H, d, J = 15.0 Hz, -CHα), 7.33–7.30 (1H, d, J = 15.0 Hz, -CHβ), 7.34 (2H, d, Ar-3CH, Ar-5CH), 7.46 (2H, d, Ar-2H, Ar-6H). 13C-NMR (500 MHz, CDCl3) δ: 193.91, 162.57, 158.93, 142.39, 136.01, 133.55, 129.54, 129.39, 129.09, 111.60, 90.69, 55.94. Molecular formula C18H17ClO4 (HRMS) Calculated = 332.7781, Observed = 333.0892.

2.1.2. (E)-3-(4-bromophenyl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one (CH2)

M.P: 120–122 °C; 1H NMR (500 MHz, CDCl3) δ: 3.77 (s, 6H, Ar-2′OCH3, Ar-6′OCH3,), 3.85 (s, 3H, Ar-4′OCH3), 6.15 (s, 2H, Ar-3′CH, Ar-5′CH), 6.96–6.93 (1H, d, J = 15.0 Hz, -CHα), 7.29–7.26 (1H, d, J = 15.0 Hz, -CHβ), 7.39–7.37 (2H, d, Ar-3CH, Ar-5CH), 7.50–7.48 (2H, d, Ar-2H, Ar-6H). 13C-NMR (500 MHz, CDCl3) δ: 193.84, 162.59, 158.95, 142.38, 134.00, 132.04, 129.75, 129.49, 124.36, 111.62, 90.71, 55.95. Molecular formula C18H17BrO4 (HRMS) Calculated = 377.2291, Observed = 377.0370.

2.1.3. (E)-3-(4-fluorophenyl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one (CH3)

M.P: 110–112 °C; 1H NMR (500 MHz, CDCl3) δ: 3.76–3.71 (s, 6H, Ar-2′OCH3, Ar-6′OCH3,), 3.86–3.82 (s, 3H, Ar-4′OCH3), 6.16 (s, 2H, Ar-3′CH, Ar-5′CH), 6.90–6.93 (1H, d, J = 15.0 Hz, -CHα), 7.35–7.32 (1H, d, J = 15.0 Hz, -CHβ), 7.03–7.07 (2H, d, Ar-3CH, Ar-5CH), 7.49–7.52 (2H, d, Ar-2H, Ar-6H). 13C-NMR (500 MHz, CDCl3) δ: 194.04, 164.85, 161.40, 158.74, 144.32, 142.72, 131.28, 130.12, 127.00, 115.87, 90.71, 55.49. Molecular formula C18H17FO4 (HRMS) Calculated = 316.3235, Observed = 317.1219.

2.1.4. (E)-3-(4-chlorophenyl)-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one (CH4)

M.P: 108–110 °C; 1H NMR (500 MHz, CDCl3) δ: 3.92 (s, 9H, Ar-2′OCH3, Ar-3′OCH3, Ar-4′OCH3), 6.76 (d, Ar-5′CH), 7.38–7.36 (d,2H, Ar-3H, Ar-5H), 7.55–7.53 (d,2H, Ar-2H, Ar-6H), 7.51 (Ar-6′CH), 7.50–7.47 (1H, d, J = 15.0 Hz, -CHα), 7.65–7.62 (1H, d, J = 15.0 Hz, -CHβ). 13C-NMR (500 MHz, CDCl3) δ: 190.56, 157.26, 153.87, 142.14, 141.37, 136.04, 133.72, 129.53, 129.18, 127.00, 126.56, 125.97, 107.41, 62.17, 61.12, 56.16. Molecular formula C18H17ClO4 (HRMS) Calculated = 332.7781, Observed = 333.0892. Molecular formula C18H17ClO4 (HRMS) Calculated = 332.7781, Observed = 333.0892.

2.1.5. (E)-3-(4-bromophenyl)-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one (CH5)

M.P: 98–100 °C; 1H NMR (500 MHz, CDCl3) δ: 3.92 (s, 9H, Ar-2′OCH3, Ar-3′OCH3, Ar-4′OCH3), 6.75 (d, 1H, Ar-5′CH), 7.38–7.36 (d,2H, Ar-3H, Ar-5H), 7.55–7.53 (d,2H, Ar-2H, Ar-6H), 7.51–7.47 (1H, Ar-6′CH), 7.51–7.48 (1H, d, J = 15.0 Hz, -CHα), 7.65–7.62 (1H, d, J = 15.0 Hz, -CHβ) 13C-NMR (500 MHz, CDCl3) δ: 190.50, 157.25, 153.87, 142.14, 141.34, 136.04, 133.71, 129.53, 129.19, 126.99, 126.56, 125.97, 107.41, 62.17, 61.12, 56.17. Molecular formula C18H17BrO4 (HRMS) Calculated = 377.2291, Observed = 377.0370.

2.1.6. (E)-3-(4-fluorophenyl)-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one (CH6)

M.P: 80–82 °C; 1H NMR (500 MHz, CDCl3) δ: 3.92 (s, 9H, Ar-2′OCH3, Ar-3′OCH3, Ar-4′OCH3), 6.75 (d, Ar-5′CH), 7.11–7.07 (d,2H, Ar-3H, Ar-5H), 7.62–7.59 (d,2H, Ar-2H, Ar-6H), 7.50 (Ar-6′CH), 7.45–7.42 (1H, d, J = 15.0 Hz, -CHα), 7.67–7.64 (1H, d, J = 15.0 Hz, -CHβ). 13C-NMR (500 MHz, CDCl3) δ: 190.63, 157.15, 153.81, 142.14, 141.67, 131.44, 131.42, 130.28, 130.21, 126.66, 126.29, 125.91, 107.41, 62.17, 61.12, 56.17. Molecular formula C18H17FO4 (HRMS) Calculated = 316.3235, Observed = 317.1219.

2.2. MAOs and BACE1 Inhibition Studies

MAO events were assessed with recombinant MAO-A and MAO-B, as well as the substrates kynuramine (0.06 mM) and benzylamine (0.3 mM). The kinetics of MAO-B were analyzed under 2.4 × Km (i.e., 0.051 mM) of benzylamine. BACE-1 was measured using a β-secretase (BACE-1) assay kit at 320 nm for excitation and 405 nm for emission using a fluorescence spectrometer. The inhibitory activities of CH1-CH6 against MAO-A, MAO-B and BACE-1 were observed at 10 µM. IC50 values of CH4 and CH5, which showed residual activities of <50% for MAO-A and MAO-B, were evaluated, as described previously. The IC50 value of CH5 for BACE-1 was also analyzed [55,56].

2.3. Enzyme Inhibition and Kinetic Studies

The inhibitory actions of the six molecules against MAO-A, MAO-B, and BACE-1 were first tested at 10 µM. Initially, the IC50 values of the compounds for MAOs were calculated [57]. At three inhibitory concentrations and five substrate concentrations, kinetic tests were conducted on CH4 and CH5, which inhibited MAO-B most potently.

2.4. Inhibitor Reversibility Analysis

Dialysis was used to assess the reversibility of MAO-B inhibitions by CH4 and CH5 after preincubating them for 30 min at 0.15 µM with MAO-B. For contrast, MAO-B was preincubated with lazabemide (a reference reversible MAO-B inhibitor) or pargyline (a reference irreversible MAO-B inhibitor) at 0.20 and 0.30 µM. Reversibility patterns were analyzed by comparing the activities of dialyzed (AD) and undialyzed (AU) samples [58].

2.5. Cytotoxicity and ROS Assay

The lead molecules CH4 and CH5 in the current series were further evaluated for their cytotoxic nature and ROS scavenging ability by the previously reported procedure [59,60] (Supplementary Material).

2.6. Blood-Brain Barrier (BBB) Permeability

The CNS bioavailability of the molecules was confirmed by a parallel artificial membrane permeability assay (PAMPA) by Di et al. [61].

2.7. Computational Studies

X-ray coordinates of the crystal structures of both the MAO isoforms and BACE-1 were retrieved from the Protein Data Bank with the entries 2Z5X, 2V5Z and 3TPP, respectively [62,63,64]. Protein and ligand structures were treated with the Protein Preparation Wizard and Ligprep Tool, respectively [65,66,67]. These preliminary steps are crucial for further docking analyses, allowing the generation of the correct protonation states at physiological pH or the generation of all allowed tautomers and possible conformations. Enclosing boxes were centered on the center of a mass of cognate ligand, and SP docking protocols were employed using GLIDE software [68]. To corroborate the reliability of docking simulations, redocking analyses were performed on the cognate ligands in their binding sites. Cognate ligands were moved back to the original positions with Root Mean Square Deviations (RMSD), considering all the heavy atoms, equal to 0.155 Å, 0.208 Å, and 0.467 Å for BACE-1, MAO-A, and MAO-B cognate ligands, respectively. Discovery Studio 2.5 software package (Accelrys, San Diego, CA, USA) was used to predict the ADMET parameters of all the molecules. The Vega and PredHerg platforms were employed to assess the mutagenicity and cardiotoxicity potentials [69,70].

3. Results

3.1. Synthesis

The synthesis of two small series of trimethoxylated halogenated chalcones was achieved by the Claisen–Schmidt condensation of 2,4,6-trimethoxy acetophenone/2,3,4-trimethoxy acetophenone with various para-substituted halogenated benzaldehydes. 1H NMR showed a sharp doublet peak for Hα and Hβ at 7.65–7.62 and 7.50–7.47, respectively. A large coupling constant of 15Hz of the double bond of chalcones revealed its trans conformation [71]. The protons of methoxy groups showed a singlet peak at 3.92, while the 13C NMR showed a peak at 55.95–62.17 for the methoxy carbon and a characteristic peak of carbonyl carbon at 190.63–193.91. The HRMS analysis showed the molecular weight of the targeted compounds [Supplementary Material].

3.2. MAO-A, MAO-B, and BACE1 Inhibition Studies

The six compounds CH1-CH6 inhibited MAO-B more effectively than MAO-A, and CH4 and CH5 revealed the most inhibitory activities against MAO-A and MAO-B at 10 µM with residual activities of <50% (Table 1). Compound CH5 most potently inhibited MAO-A with an IC50 value of 0.46 µM, followed by CH4 (IC50 = 0.84 µM). In the compounds, 2′,3′,4′-methoxy moiety in CH4-CH6 was more effective for MAO-B inhibition than 2′,4′,6′-methoxy moiety in CH1-CH3. In 2′,3′,4′-methoxy derivatives (CH4-CH6), inhibitory activities against MAO-B increased in the order of –Br in CH5 > –Cl in CH4 > –F in CH6 at para-position in ring B. CH5 and CH4 were selective for MAO-B with selectivity index (SI) values of 31.3 and 15.1, respectively, over MAO-A. No compounds effectively inhibited BACE-1, except CH4 and CH5, which moderately inhibited BACE-1 with IC50 values of 13.6 and 19.8 µM, respectively (Table 1). The IC50 value of CH4 for BACE-1 (13.6 µM) was similar to that of reference quercetin (IC50 = 13.4 µM)
Based upon the above small selected library of compounds, it is possible to expand some interesting structure–activity relationships (SARs) on the basis of the orientation pattern of methoxyl groups on the various positions of phenyl ring A and the presence of various halogens on the para-position of ring B of chalcones. The results clearly documented that all the trimethoxylated halogenated derivatives showed moderate to good inhibition of MAO-B as compared to MAO-A. Considering the orientation pattern, it is clearly understood that introduction of methoxyl groups on the 2′, 4′, and 6′ positions does not have much influence when compared with the positions of 2′, 3′, and 4′. This suggests that the crowding of methoxyl groups without the separation of a carbon atom on the A ring is crucial for the activity. As regards halogen substitution on the B ring, bromine or chlorine improved MAO-B inhibitory activity when compared to fluorine substitution (the residual activities were 0.93% and 0.38% at 10.0 μM, respectively).
The two representative MAO-B inhibitors, CH4 and CH5, showed good BACE-1 inhibition with 54.3% and 64.3% residual activity, respectively, at 10.0 μM. The IC50 value of the BACE-1 inhibition of CH4 was 13.6 μM, which, interestingly, is very close to the standard value. In BACE-1 inhibition, both chlorine and bromine have a large impact on the fluorine substitution

3.3. Kinetic Study

Kinetic experiments were carried out at five concentrations of the substrates and three inhibitor concentrations. In the kinetic studies of MAO-B binding by CH4 and CH5, Lineweaver–Burk plots showed that CH4 and CH5 were competitive inhibitors of MAO-B (Figure 1a,c), and their secondary plots showed that their Ki values were 0.68 ± 0.17 and 0.31 ± 0.014 µM, respectively (Figure 1b,d). These results suggest that CH4 and CH5 compete with the substrate at the active site of MAO-B.

3.4. Reversibility Studies

The reversibilities of the inhibitions were analyzed using dialysis after preincubating MAO-B with CH4 or CH5 for 30 min, as previously described. In the experiments, the concentrations used were the following: CH4 at 1.68 µM, CH5 at 0.92 µM, lazabemide (a reference reversible inhibitor) at 0.22 µM, and pargyline (a reference irreversible inhibitor) at 0.28 µM. The relative activities for undialyzed (AU) and dialyzed (AD) samples were compared to determine the reversibility patterns. In reversibility experiments using dialysis, the inhibition of MAO-B by CH4 and CH5 was recovered from 30.9% (AU) to 96.9% (AD), and from 37.2% to 73.8%, respectively (Figure 2). The recovery values were indistinguishable to those of the reversible reference lazabemide (from 33.0% to 89.2%), contrary to the inhibition of MAO-B by the irreversible inhibitor pargyline, which was not recovered (i.e., from 37.2% to 38.5%). These experiments indicated that CH4 and CH5 were reversible inhibitors of MAO-B.

3.5. Blood–Brain Barrier (BBB) Permeation Studies

From the assay, highly effective permeabilities and high CNS bioavailabilities were observed for the halogenated chalcones with Pe ranges of 13.22~15.65 × 10−6 cm/s (Table 2). All halogenated substituted derivatives showed higher CNS permeabilities than unsubstituted ones.

3.6. In Vitro Toxicity Evaluation

An in vitro toxicity evaluation of CH4 and CH5 was carried out using an MTT assay. We used the African Green Monkey kidney cell line (Vero) as a valuable in vitro model for basal toxicity studies [72]. To check the toxicity of the tested compounds, the Vero cell line was incubated with different concentrations of CH4 and CH5 (1 to 500 µg/mL), and the relative cell viability was measured after 48 h. Both the compounds induced toxicity at concentrations higher than 200 µg/mL (Figure 3A and Figure 4A). The result of the cell viability assay was represented as a dose–response curve using the GraphPad Prism 6.0 software (USA). The IC50 value was calculated at a 198.5 µg/mL for CH4 (Figure 3B) and 126.4 µg/mL for CH5 (Figure 4B). The reduction in cell number and also the membrane damage were very evident in treatment with CH4 and CH5 at IC50 and higher concentrations, as analyzed by phase-contrast microscope. These two experiments strongly support that CH4 and CH5 are one hundred times safer than the effective concentration of one micromolar (Figure 3C and Figure 4C). Both results demonstrate that the undesired changes in membrane integrity and a reduction in cell number are indicative of oxidative stress only at higher concentrations.

3.7. ROS Assay

Our next attempt was to study the effect of CH4 and CH5 on inhibiting the excess reactive oxygen species (ROS) involved in the pathogenesis of neurodegenerative diseases. This ROS causes neuronal damage via oxidative damage in the brain during neurodegenerative diseases [73,74]. We examined the intracellular ROS generation on Vero cell cultures after exposure to exogenous H2O2. During our experiment, it was noted H2O2-treated Vero cells had a higher ROS generation. When we incubated Vero cells with CH4 and CH5 at IC50, we observed a decrease in ROS levels compared with non-treated cells (Figure 5a,b). Based on this observation, it is understood that the disruption of the balance between pro-oxidant and antioxidant levels can be retained by CH4 and CH5 at IC50 concentrations.

3.8. Computational Studies

Compounds CH5 and CH4 can bind the MAO-A binding pocket with similar posing (Figure 6). The para-bromine and para-fluorine styrene can establish Pi–Pi interactions with F208, and tri-methoxy phenyl rings can cause Pi–Pi interaction with Y407, facing FAD. Docking score values were equal to −6.416 kcal/mol and −6.465 kcal/mol for CH5 and CH4, respectively. As far as MAO-B is concerned, the para-bromine and para-fluorine styrene can interact with the MAO-B-selective residue Y326, and trimethoxy phenyl rings face the FAD cofactor, forming Pi–Pi interactions with the side chain of the Y398 aromatic residue (Figure 7). Docking score values were equal to −9.824 kcal/mol and −10.251 kcal/mol for CH5 and CH4, respectively. As far as BACE-1 is concerned, compounds CH5 and CH4 can establish mainly hydrophobic interactions. In particular, the tri-methoxy aromatic rings can face a hydrophobic region made by side chains of F108 and I118, and the halogenated styrene moieties take place towards Y14 side chain (Figure 8). Docking score values were equal to −6.749 kcal/mol and −6.762 kcal/mol for CH5 and CH4, respectively.
Computational analyses were performed in order to shed light on the interactions behind the higher affinity towards MAO-B. The interaction between CH5 and CH4 with Y326 MAO-B selective residue is crucial for enhancing activity and selectivity towards MAO-B. Furthermore, despite the binding poses of the two compounds being similar between MAO binding pockets, the gap between the docking score values towards the two receptors significantly favors MAO-B. For this reason, a more detailed analysis of the terms that constitute the GLIDE scoring function was performed, revealing that the Glide energy term values, which are a sum of van der Waals and Coulomb energy terms, were equal to −50.263 kcal/mol and −46.128 kcal/mol for CH4 and CH5 bonded to MAO-B, respectively, and −21.341 kcal/mol and −23.449 kcal/mol for CH5 and CH4 bonded to MAO-A, respectively, thus considerably favoring the binding to MAO-B. Regarding computational simulations of BACE-1, the binding was mainly due to hydrophobic interactions and the Glide energy term values were equal to −46.583 kcal/mol and −45.809 kcal/mol, thus comparable to those of MAO-B.
On the basis of ADME prediction, all the compounds in the present study showed good absorption and BBB permeability, at 99% and 95%, respectively (Figure 9). A drug target matching analysis was also performed by using our predictive platform MuSSel (Multifingerprint Similarity Search aLgorithm) [75,76]. It is notable that MAO-A and MAO-B were predicted as reliable targets for CH4 and CH5 [Supplementary Material].
Finally, we predicted the mutagenicity and cardiotoxicity potentials for CH4 and CH5 [77]. These are two relevant toxicity endpoints of the utmost importance to prioritize compounds in early stages of drug discovery and are often behind the attrition of preclinical and clinical studies [78,79]. Regarding the mutagenicity, four non-test predictive models (i.e., CAESAR model version 2.1.13; SARpy/IRFMN model version 1.0.7; ISS model version 1.0.2; KNN/read-across model version 1.0.0) were employed in consensus to provide a qualitative assessment of the mutagenic potentials of CH4 and CH5 [80]. Interestingly, both the compounds were found to be non-mutagenic [Supplementary Materials]. Predictive QSAR models of hERG blockage were employed for cardiotoxicity analysis [81]. In the results, CH4 was returned to be non-cardiotoxic, while CH5 was flagged as potentially weak cardiotoxic (Supplementary Materials).

4. Conclusions

In summary, two sets of trimethoxylated halogenated chalcones were synthesized, characterized, and evaluated for their MAO and BACE-1 inhibitory activities. CH4 and CH5 were revealed as competitive and reversible inhibitors of MAO-B, with Ki values of 0.68 ± 0.17 and 0.31 ± 0.014 µM, respectively. On the other hand, CH4 and CH5 showed good BACE-1 inhibition with IC50 values of 13.6 and 19.8 μM, respectively. Additionally, CH4 and CH5 were found to be safe as analyzed by an in-vitro toxicity study. Additionally, the pro-oxidant and antioxidant levels can be retained by CH4 and CH5. These results suggest that CH4 and CH5 could be considered as a potential multi-targeted ligand for the treatment of neurological disorders.

Supplementary Materials

Available online at https://0-www-mdpi-com.brum.beds.ac.uk/article/10.3390/pharmaceutics13060850/s1, spectral interpretation; cytotoxicity studies; ROS Assay; MUSSEL Prediction; Toxicity Predicition.

Author Contributions

Conceptualization: B.M. and H.K.; synthesis: V.P.K., A.S.N. and B.M.; biological activity: J.M.O., A.K., M.A.A. and L.R.N.; docking analysis: N.G., F.C. and O.N.; original draft writing: B.M.; review and editing: H.K. and B.M.; supervision: H.K.; funding acquisition: H.K. and A.K. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the National Research Foundation of Korea (NRF) grant provided by the Korean Government (NRF-2019R1A2C1088967 to H. Kim), Republic of Korea, and by a grant from Amrita Vishwa Vidyapeetham University (Seed Grant Number K-PHAR-20-628 to B. Mathew).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data generated or analyzed during this study have been included in this article.

Acknowledgments

Authors acknowledge Taif University Researchers Supporting Project number (TURSP-2020/68), Taif University, Taif, Saudi Arabia.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Youdim, M.B.; Edmondson, D.; Tipton, K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 2006, 7, 295–309. [Google Scholar] [CrossRef]
  2. Carradori, S.; Secci, D.; Petzer, J.P. MAO inhibitors and their wider applications: A patent review. Expert Opin. Ther. Pat. 2018, 28, 211–226. [Google Scholar] [CrossRef]
  3. Manzoor, S.; Hoda, N. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer’s disease agents: A review. Eur. J. Med. Chem. 2020, 206, 112787. [Google Scholar] [CrossRef] [PubMed]
  4. Dezsi, L.; Vecsei, L. Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol. Disord. Drug Targets 2017, 16, 425–439. [Google Scholar] [CrossRef] [PubMed]
  5. Riederer, P.; Müller, T. Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opin. Drug Metab. Toxicol. 2017, 13, 233–240. [Google Scholar] [CrossRef]
  6. Tripathi, R.K.P.; Ayyannan, S.R. Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update. Med. Res. Rev. 2019, 39, 1603–1706. [Google Scholar] [CrossRef]
  7. Guglielmi, P.; Carradori, S.; Ammazzalorso, A.; Secci, D. Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: Is there room for improvement? Expert Opin. Drug Discov. 2019, 14, 995–1035. [Google Scholar] [CrossRef] [PubMed]
  8. Hong, R.; Li, X. Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches. Medchemcomm 2018, 10, 10–25. [Google Scholar] [CrossRef] [PubMed]
  9. Youdim, M.B.; Bakhle, Y.S. Monoamine oxidase: Isoforms and inhibitors in Parkinson’s disease and depressive illness. Br. J. Pharmacol. 2006, 147, S287–S296. [Google Scholar] [CrossRef] [Green Version]
  10. Ramsay, R.R.; Albreht, A. Kinetics, mechanism, and inhibition of monoamine oxidase. J. Neural Transm. 2018, 125, 1659–1683. [Google Scholar] [CrossRef] [Green Version]
  11. Ghosh, A.K.; Osswald, H.L. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer’s disease. Chem. Soc. Rev. 2014, 43, 6765–6813. [Google Scholar] [CrossRef] [Green Version]
  12. Kumar, D.; Ganeshpurkar, A.; Kumar, D.; Modi, G.; Gupta, S.K.; Singh, S.K. Secretase inhibitors for the treatment of Alzheimer’s disease: Long road ahead. Eur. J. Med. Chem. 2018, 148, 436–452. [Google Scholar] [CrossRef] [PubMed]
  13. Moussa-Pacha, N.M.; Abdin, S.M.; Omar, H.A.; Alniss, H.; Al-Tel, T.H. BACE1 inhibitors: Current status and future directions in treating Alzheimer’s disease. Med. Res. Rev. 2020, 40, 339–384. [Google Scholar] [CrossRef]
  14. León, R.; Garcia, A.G.; Marco-Contelles, J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med. Res. Rev. 2013, 33, 139–189. [Google Scholar] [CrossRef] [PubMed]
  15. Schaduangrat, N.; Prachayasittikul, V.; Choomwattana, S.; Wongchitrat, P.; Phopin, K.; Suwanjang, W.; Malik, A.A.; Vincent, B.; Nantasenamat, C. Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer’s disease. Med. Res. Rev. 2019, 39, 1730–1778. [Google Scholar] [CrossRef] [PubMed]
  16. Huang, C.; Zhang, W.; Sheng, C.; Zhang, W.; Xing, C.; Miao, Z. Chalcone: A privileged structure in medicinal chemistry. Chem. Rev. 2017, 117, 7762–7810. [Google Scholar]
  17. Matos, M.J.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L. Potential pharmacological uses of chalcones: A patent review. Expert Opin. Ther. Pat. 2015, 25, 351–366. [Google Scholar] [CrossRef]
  18. Singh, P.; Anand, A.; Kumar, V. Recent developments in biological activities of chalcones: A mini review. Eur. J. Med. Chem. 2014, 85, 758–777. [Google Scholar] [CrossRef]
  19. Sharma, R.; Kumar, R.; Kodwani, R.; Kapoor, S.; Khare, A.; Bansal, R.; Khurana, S.; Singh, S.; Thomas, J.; Roy, B.; et al. A review on mechanisms of anti tumor activity of chalcones. Anticancer Agents Med. Chem. 2015, 16, 200–211. [Google Scholar] [CrossRef]
  20. Nowakowska, Z. A review of anti-infective and anti-inflammatory chalcones. Eur. J. Med. Chem. 2007, 42, 125–137. [Google Scholar] [CrossRef]
  21. Rocha, S.; Ribeiro, D.; Fernandes, E.; Freitas, M. A systematic review on anti-diabetic properties of chalcones. Curr. Med. Chem. 2020, 27, 2257–2321. [Google Scholar] [CrossRef]
  22. Mathew, B.; Parambi, D.G.T.; Sivasankarapillai, V.S.; Uddin, M.S.; Suresh, J.; Mathew, G.E.; Joy, M.; Marathakam, A.; Gupta, S.V. Perspective design of chalcones for the management of CNS disorders: A mini-review. CNS Neurol. Disord. Drug Targets 2019, 18, 432–445. [Google Scholar] [CrossRef]
  23. Wilcken, R.; Zimmermann, M.O.; Lange, A.; Joerger, A.C.; Boeckler, F.M. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J. Med. Chem. 2013, 56, 1363–1388. [Google Scholar] [CrossRef] [PubMed]
  24. Lu, Y.; Wang, Y.; Xu, Z.; Yan, X.; Luo, X.; Jiang, H.; Zhu, W. C-X⋯H contacts in biomolecular systems: How they contribute to protein-ligand binding affinity. J. Phys. Chem. B. 2009, 113, 12615–12621. [Google Scholar] [CrossRef] [PubMed]
  25. Mathew, B.; Carradori, S.; Guglielmi, P.; Uddin, M.S.; Kim, H. New aspects of monoamine oxidase b inhibitors: The key role of halogens to open the golden door. Curr. Med. Chem. 2021, 28, 266–283. [Google Scholar] [CrossRef] [PubMed]
  26. Mathew, B.; Mathew, G.E.; Uçar, G.; Baysal, I.; Suresh, J.; Vilapurathu, J.K.; Prakasan, A.; Suresh, J.K.; Thomas, A. Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: Synthesis, biochemistry and molecular docking studies. Bioorg. Chem. 2015, 62, 22–29. [Google Scholar] [CrossRef]
  27. Morales-Camilo, N.; Salas, C.O.; Sanhueza, C.; Espinosa-Bustos, C.; Sepúlveda-Boza, S.; Reyes-Parada, M.; Gonzalez-Nilo, F.; Caroli-Rezende, M.; Fierro, A. Synthesis, biological evaluation, and molecular simulation of chalcones and aurones as selective MAO-B inhibitors. Chem. Biol. Drug Des. 2015, 85, 685–695. [Google Scholar] [CrossRef]
  28. Choi, J.W.; Jang, B.K.; Cho, N.C.; Park, J.H.; Yeon, S.K.; Ju, E.J.; Lee, Y.S.; Han, G.; Pae, A.N.; Kim, D.J.; et al. Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. Bioorg. Med. Chem. 2015, 23, 6486–6496. [Google Scholar] [CrossRef]
  29. Hammuda, A.; Shalaby, R.; Rovida, S.; Edmondson, D.E.; Binda, C.; Khalil, A. Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors. Eur. J. Med. Chem. 2016, 114, 162–169. [Google Scholar] [CrossRef]
  30. Mathew, B.; Uçar, G.; Mathew, G.E.; Mathew, S.; Purapurath, K.P.; Moolayil, F.; Mohan, S.; Gupta, S.V. Monoamine oxidase inhibitory activity: Methyl- versus Chloro chalcone derivatives. Chem. Med. Chem. 2016, 11, 2649–2655. [Google Scholar] [CrossRef]
  31. Mathew, B.; Mathew, G.E.; Ucar, G.; Joy, M.; Nafna, E.K.; Lohidakshan, K.K.; Suresh, J. Monoamine oxidase inhibitory activity of methoxy-substituted chalcones. Int. J. Biol. Macromol. 2017, 104, 1321–1329. [Google Scholar] [CrossRef] [PubMed]
  32. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Rossi, F.; Yáñez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Chalcones: A valid scaffold for monoamine oxidases inhibitors. J. Med. Chem. 2009, 52, 2818–2824. [Google Scholar] [CrossRef]
  33. Minders, C.; Petzer, J.P.; Petzer, A.; Lourens, A.C. Monoamine oxidase inhibitory activities of heterocyclic chalcones. Bioorg. Med. Chem. Lett. 2015, 25, 5270–5276. [Google Scholar] [CrossRef]
  34. Sasidharan, R.; Manju, S.L.; Uçar, G.; Baysal, I.; Mathew, B. Identification of indole-based chalcones: Discovery of a potent, selective, and reversible class of MAO-B inhibitors. Arch. Pharm. 2016, 349, 627–637. [Google Scholar] [CrossRef]
  35. Mathew, B.; Haridas, A.; Uçar, G.; Baysal, I.; Joy, M.; Mathew, G.E.; Lakshmanan, B.; Jayaprakash, V. Synthesis, biochemistry, and computational studies of brominated thienyl chalcones: A new class of reversible MAO-B Inhibitors. Chem. Med. Chem. 2016, 11, 1161–1171. [Google Scholar] [CrossRef] [PubMed]
  36. Xiao, G.; Li, Y.; Qiang, X.; Xu, R.; Zheng, Y.; Cao, Z.; Luo, L.; Yang, X.; Sang, Z.; Su, F.; et al. Design, synthesis and biological evaluation of 4′-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease. Bioorg. Med. Chem. 2017, 25, 1030–1041. [Google Scholar] [CrossRef]
  37. Cao, Z.; Yang, J.; Xu, R.; Song, Q.; Zhang, X.; Liu, H.; Qiang, X.; Li, Y.; Tan, Z.; Deng, Y. Design, synthesis and evaluation of 4′-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer’s disease treatment. Bioorg. Med. Chem. 2018, 26, 1102–1115. [Google Scholar] [CrossRef]
  38. Sasidharan, R.; Baek, S.C.; Sreedharannair Leelabaiamma, M.; Kim, H.; Mathew, B. Imidazole bearing chalcones as a new class of monoamine oxidase inhibitors. Biomed. Pharmacother. 2018, 106, 8–13. [Google Scholar] [CrossRef] [PubMed]
  39. Suresh, J.; Baek, S.C.; Ramakrishnan, S.P.; Kim, H.; Mathew, B. Discovery of potent and reversible MAO-B inhibitors as furanochalcones. Int. J. Biol. Macromol. 2018, 108, 660–664. [Google Scholar] [CrossRef]
  40. Reeta; Baek, S.C.; Lee, J.P.; Rangarajan, T.M.; Ayushee; Singh, R.P.; Singh, M.; Mangiatordi, G.F.; Nicolotti, O.; Kim, H.; et al. Ethyl acetohydroxamate incorporated chalcones: Unveiling a novel class of chalcones for multitarget monoamine oxidase-B inhibitors against Alzheimer’s disease. CNS Neurol. Disord. Drug Targets 2019, 18, 643–654. [Google Scholar] [CrossRef]
  41. Mathew, B.; Baek, S.C.; Thomas Parambi, D.G.; Lee, J.P.; Mathew, G.E.; Jayanthi, S.; Vinod, D.; Rapheal, C.; Devikrishna, V.; Kondarath, S.S.; et al. Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: Fluorinated chalcones of morpholine versus imidazole. Arch. Pharm. 2019, 352, e1800309. [Google Scholar] [CrossRef] [PubMed]
  42. Parambi, D.G.T.; Oh, J.M.; Baek, S.C.; Lee, J.P.; Tondo, A.R.; Nicolotti, O.; Kim, H.; Mathew, B. Design, synthesis and biological evaluation of oxygenated chalcones as potent and selective MAO-B inhibitors. Bioorg. Chem. 2019, 93, 103335. [Google Scholar] [CrossRef]
  43. Sang, Z.; Wang, K.; Zhang, P.; Shi, J.; Liu, W.; Tan, Z. Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2019, 180, 238–252. [Google Scholar] [CrossRef]
  44. Zhang, X.; Song, Q.; Cao, Z.; Li, Y.; Tian, C.; Yang, Z.; Zhang, H.; Deng, Y. Design, synthesis and evaluation of chalcone Mannich base derivatives as multifunctional agents for the potential treatment of Alzheimer’s disease. Bioorg. Chem. 2019, 87, 395–408. [Google Scholar] [CrossRef]
  45. Shalaby, R.; Petzer, J.P.; Petzer, A.; Ashraf, U.M.; Atari, E.; Alasmari, F.; Kumarasamy, S.; Sari, Y.; Khalil, A. SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs. J. Enzyme Inhib. Med. Chem. 2019, 34, 863–876. [Google Scholar] [CrossRef] [Green Version]
  46. Bai, P.; Wang, K.; Zhang, P.; Shi, J.; Cheng, X.; Zhang, Q.; Zheng, C.; Cheng, Y.; Yang, J.; Lu, X.; et al. Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer’s disease. Eur. J. Med. Chem. 2019, 183, 111737. [Google Scholar] [CrossRef] [PubMed]
  47. Oh, J.M.; Rangarajan, T.M.; Chaudhary, R.; Singh, R.P.; Singh, M.; Singh, R.P.; Tondo, A.R.; Gambacorta, N.; Nicolotti, O.; Mathew, B.; et al. Novel class of chalcone oxime ethers as potent monoamine oxidase-B and acetylcholinesterase inhibitors. Molecules 2020, 25, 2356. [Google Scholar] [CrossRef]
  48. Jeong, G.S.; Kaipakasseri, S.; Lee, S.R.; Marraiki, N.; Batiha, G.E.; Dev, S.; Palakkathondi, A.; Kavully, F.S.; Gambacorta, N.; Nicolotti, O.; et al. Selected 1,3-benzodioxine-containing chalcones as multipotent oxidase and acetylcholinesterase inhibitors. ChemMedChem 2020, 15, 2257–2263. [Google Scholar] [CrossRef] [PubMed]
  49. Kong, Z.; Sun, D.; Jiang, Y.; Hu, Y. Design, synthesis, and evaluation of 1, 4-benzodioxan-substituted chalcones as selective and reversible inhibitors of human monoamine oxidase B. J. Enzyme Inhib. Med. Chem. 2020, 35, 1513–1523. [Google Scholar] [CrossRef] [PubMed]
  50. Sasidharan, R.; Eom, B.H.; Heo, J.H.; Park, J.E.; Abdelgawad, M.A.; Musa, A.; Gambacorta, N.; Nicolotti, O.; Manju, S.L.; Mathew, B.; et al. Morpholine-based chalcones as dual-acting monoamine oxidase-B and acetylcholinesterase inhibitors: Synthesis and biochemical investigations. J. Enzyme Inhib. Med. Chem. 2021, 36, 188–197. [Google Scholar] [CrossRef] [PubMed]
  51. Zhang, X.; Rakesh, K.P.; Bukhari, S.N.A.; Balakrishna, M.; Manukumar, H.M.; Qin, H.L. Multi-targetable chalcone analogs to treat deadly Alzheimer’s disease: Current view and upcoming advice. Bioorg. Chem. 2018, 80, 86–93. [Google Scholar] [CrossRef] [PubMed]
  52. Guglielmi, P.; Mathew, B.; Secci, D.; Carradori, S. Chalcones: Unearthing their therapeutic possibility as monoamine oxidase B inhibitors. Eur. J. Med. Chem. 2020, 205, 112650. [Google Scholar] [CrossRef]
  53. Mathew, B. Privileged pharmacophore of FDA approved drugs in combination with chalcone framework: A new hope for alzheimer’s treatment. Comb. Chem. High Throughput Screen. 2020, 23, 842–846. [Google Scholar] [CrossRef] [PubMed]
  54. Burmaoglu, S.; Kazancioglu, E.A.; Kaya, R.; Kazancioglu, M.; Karaman, M.; Algul, O.; Gulcin, I. Synthesis of novel organohalogen chalcone derivatives and screening of their molecular docking study and some enzymes inhibition effects. J. Mol. Struct. 2020, 1208, 127868. [Google Scholar] [CrossRef]
  55. Mathew, B.; Baek, S.C.; Grace Thomas Parambi, D.; Pil Lee, J.; Joy, M.; Annie Rilda, P.R.; Randev, R.V.; Nithyamol, P.; Vijayan, V.; Inasu, S.T.; et al. Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors. MedChemComm 2018, 9, 1871–1881. [Google Scholar] [CrossRef]
  56. Mathew, B.; Oh, J.M.; Baty, R.S.; Batiha, G.E.; Parambi, D.G.T.; Gambacorta, N.; Nicolotti, O.; Kim, H. Piperazine-substituted chalcones: A new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders. Environ. Sci. Pollut. Res. 2021. [Google Scholar] [CrossRef] [PubMed]
  57. Nair, A.S.; Oh, J.-M.; Koyiparambath, V.P.; Kumar, S.; Sudevan, S.T.; Soremekun, O.; Soliman, M.E.; Khames, A.; Abdelgawad, M.A.; Pappachen, L.K.; et al. Development of halogenated pyrazolines as selective monoamine oxidase-B Inhibitors: Deciphering via molecular dynamics approach. Molecules 2021, 26, 3264. [Google Scholar] [CrossRef] [PubMed]
  58. Oh, J.M.; Jang, H.J.; Kim, W.J.; Kang, M.G.; Baek, S.C.; Lee, J.P.; Park, D.; Oh, S.R.; Kim, H. Calycosin and 9-O-methylretusin isolated from Maackia amurensis as potent and selective reversible inhibitors of human monoamine oxidase-B. Int. J. Biol. Macromol. 2020, 151, 441–448. [Google Scholar] [CrossRef] [PubMed]
  59. Fotakis, G.; Timbrell, J.A. In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol. Lett. 2006, 160, 171–177. [Google Scholar] [CrossRef] [PubMed]
  60. Jambunathan, N. Determination and detection of reactive oxygen species (ROS), lipid peroxidation, and electrolyte leakage in plants. Methods Mol. Biol. 2010, 639, 292–298. [Google Scholar]
  61. Di, L.; Kerns, E.H.; Fan, K.; McConnell, O.J.; Carter, G.T. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 2003, 38, 223–232. [Google Scholar] [CrossRef]
  62. Son, S.Y.; Ma, J.; Kondou, Y.; Yoshimura, M.; Yamashita, E.; Tsukihara, T. Structure of human monoamine oxidase A at 2.2-A resolution: The control of opening the entry for substrates/inhibitors. Proc. Natl. Acad. Sci. USA 2008, 105, 5739–5744. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.E.; Mattevi, A. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs. J. Med. Chem. 2007, 50, 5848–5852. [Google Scholar] [CrossRef]
  64. Xu, Y.; Li, M.; Greenblatt, H.; Chen, W.; Paz, A.; Dym, O.; Peleg, Y.; Chen, T.; Shen, X.; He, J.; et al. Flexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulations. Acta Cryst. D 2012, 68, 13–25. [Google Scholar] [CrossRef]
  65. Schrödinger Release 2020-4: Protein Preparation Wizard; Epik, Schrödinger, LLC: New York, NY, USA, 2016.
  66. Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and Ligand Preparation: Parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided. Mol. Des. 2013, 27, 221–234. [Google Scholar] [CrossRef]
  67. Schrödinger Release 2020-4: LigPrep; Schrödinger, LLC: New York, NY, USA, 2020.
  68. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739–1749. [Google Scholar] [CrossRef]
  69. Available online: http://www.caesar-project.eu (accessed on 21 May 2021).
  70. Available online: http://predherg.labmol.com.br/ (accessed on 21 May 2021).
  71. Mathew, B.; Adeniyi, A.A.; Joy, M.; Mathew, G.E.; Ashona Singh-Pillay, A.S.; Sudarsanakumar, C.; Soliman, M.E.S.; Suresh, J. Anti-oxidant behavior of functionalized chalcone-a combined quantum chemical and crystallographic structural investigation. J. Mol. Struct. 2017, 1146, 301–308. [Google Scholar] [CrossRef]
  72. Kumar, V.; Sharma, N.; Maitra, S.S. In vitro and in vivo toxicity assessment of nanoparticles. Int. Nano Lett. 2007, 7, 243–256. [Google Scholar] [CrossRef] [Green Version]
  73. Zuo, L.; Zhou, T.; Pannell, B.K.; Ziegler, A.C.; Best, T.M. Biological and physiological role of reactive oxygen species—The good, the bad and the ugly. Acta Physiol. (Oxf.) 2015, 214, 329–348. [Google Scholar] [CrossRef]
  74. Park, C.; Cha, H.J.; Hong, S.H.; Kim, G.Y.; Kim, S.; Kim, H.S.; Kim, B.W.; Jeon, Y.J.; Choi, Y.H. Protective effect of phloroglucinol on oxidative stress-induced DNA damage and apoptosis through activation of the Nrf2/HO-1 signaling pathway in HaCaT human keratinocytes. Mar. Drugs 2019, 17, 225. [Google Scholar] [CrossRef] [Green Version]
  75. Alberga, D.; Trisciuzzi, D.; Montaruli, M.; Leonetti, F.; Mangiatordi, G.F.; Nicolotti, O. A new approach for drug target and bioactivity prediction: The multifingerprint similarity search algorithm (MuSSeL). J. Chem. Inf. Model. 2019, 59, 586–596. [Google Scholar] [CrossRef]
  76. Montaruli, M.; Alberga, D.; Ciriaco, F.; Trisciuzzi, D.; Tondo, A.R.; Mangiatordi, G.F.; Nicolotti, O. Accelerating drug discovery by early protein drug target prediction based on a multi-fingerprint similarity search. Molecules 2019, 24, 2233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Nicolotti, O.; Benfenati, E.; Carotti, A.; Gadaleta, D.; Gissi, A.; Mangiatordi, G.F.; Novellino, E. REACH and in silico methods: An attractive opportunity for medicinal chemists. Drug Discov. Today 2014, 19, 1757–1768. [Google Scholar] [CrossRef] [PubMed]
  78. Cavalluzzi, M.M.; Imbrici, P.; Gualdani, R.; Stefanachi, A.; Mangiatordi, G.F.; Lentini, G.; Nicolotti, O. Human ether-à-go-go-related potassium channel: Exploring SAR to improve drug design. Drug Discov. Today 2020, 25, 344–366. [Google Scholar] [CrossRef] [PubMed]
  79. Mangiatordi, G.F.; Alberga, D.; Altomare, C.D.; Carotti, A.; Catto, M.; Cellamare, S.; Gadaleta, D.; Lattanzi, G.; Leonetti, F.; Pisani, L.; et al. Mind the gap! A journey towards computational toxicology. Mol. Inform. 2016, 35, 294–308. [Google Scholar] [CrossRef] [PubMed]
  80. Ferrari, T.; Gini, G. An open source multistep model to predict mutagenicity from statistical analysis and relevant structural alerts. Chem Cent. J. 2010, 4, S2. [Google Scholar] [CrossRef] [Green Version]
  81. Braga, R.C.; Alves, V.M.; Silva, M.F.; Muratov, E.; Fourches, D.; Lião, L.M.; Tropsha, A.; Andrade, C.H. Pred-hERG: A novel web-accessible computational tool for predicting cardiac toxicity. Mol. Inform. 2015, 34, 698–701. [Google Scholar] [CrossRef] [Green Version]
Pharmaceutics 13 00850 sch001 550
Scheme 1. Synthetic route for (CH1–CH6) series.
Scheme 1. Synthetic route for (CH1–CH6) series.
Pharmaceutics 13 00850 sch001
Pharmaceutics 13 00850 g001 550
Figure 1. Lineweaver–Burk plots for MAO-B inhibition by CH4 and CH5 (a,c), and their respective secondary plots (b,d) of the slopes vs. inhibitor concentrations.
Figure 1. Lineweaver–Burk plots for MAO-B inhibition by CH4 and CH5 (a,c), and their respective secondary plots (b,d) of the slopes vs. inhibitor concentrations.
Pharmaceutics 13 00850 g001
Pharmaceutics 13 00850 g002 550
Figure 2. Recoveries of MAO-B inhibitions by CH4 and CH5 using dialysis experiments.
Figure 2. Recoveries of MAO-B inhibitions by CH4 and CH5 using dialysis experiments.
Pharmaceutics 13 00850 g002
Pharmaceutics 13 00850 g003 550
Figure 3. Evaluation of CH4 effect on cell viability in Vero cell line. (A) Cell viability; a very high percentage of viable cells (>90%) up to 200 µg/mL. (B) Representation of a dose–response curve and IC50; 198.5 µg/mL according to GraphPad Prism 6.0 software (USA). (C) Morphological observation of Vero cells in treatment with different concentrations under phase-contrast microscope. Vero cells were incubated with CH4 for 48 h, and cell viability was calculated by MTT assay as described in “Experimental Procedures.” Untreated cells (control) were considered to have 100% viability.
Figure 3. Evaluation of CH4 effect on cell viability in Vero cell line. (A) Cell viability; a very high percentage of viable cells (>90%) up to 200 µg/mL. (B) Representation of a dose–response curve and IC50; 198.5 µg/mL according to GraphPad Prism 6.0 software (USA). (C) Morphological observation of Vero cells in treatment with different concentrations under phase-contrast microscope. Vero cells were incubated with CH4 for 48 h, and cell viability was calculated by MTT assay as described in “Experimental Procedures.” Untreated cells (control) were considered to have 100% viability.
Pharmaceutics 13 00850 g003
Pharmaceutics 13 00850 g004 550
Figure 4. Evaluation of CH5 effect on cell viability in Vero cell line. (A) Cell viability; a very high percentage of viable cells (>90%) up to 100 times the effective concentration. (B) Representation of a dose–response curve and IC50; 126.4 µg/mL. (C) Morphological observation of Vero cells on treatment with different concentration under phase-contrast microscope. Vero cells were incubated with CH5 for 48 h, and cell viability was calculated by MTT assay as described in “Experimental Procedures.” Untreated cells (control) were considered to have 100% viability.
Figure 4. Evaluation of CH5 effect on cell viability in Vero cell line. (A) Cell viability; a very high percentage of viable cells (>90%) up to 100 times the effective concentration. (B) Representation of a dose–response curve and IC50; 126.4 µg/mL. (C) Morphological observation of Vero cells on treatment with different concentration under phase-contrast microscope. Vero cells were incubated with CH5 for 48 h, and cell viability was calculated by MTT assay as described in “Experimental Procedures.” Untreated cells (control) were considered to have 100% viability.
Pharmaceutics 13 00850 g004
Pharmaceutics 13 00850 g005 550
Figure 5. Effects of CH4 (a) and CH5 (b) on Vero cells treated with H2O2 to induce ROS. Vero cells were treated with 100 µg/mL of 30% H2O2, and the production of ROS was evaluated immediately as described in “Experimental Procedures”.
Figure 5. Effects of CH4 (a) and CH5 (b) on Vero cells treated with H2O2 to induce ROS. Vero cells were treated with 100 µg/mL of 30% H2O2, and the production of ROS was evaluated immediately as described in “Experimental Procedures”.
Pharmaceutics 13 00850 g005
Pharmaceutics 13 00850 g006 550
Figure 6. Zoomed in view of an MAO-A binding pocket. Panels (a,b) reported the best pose returned from docking analysis for CH5 (green sticks) and CH4 (yellow sticks), respectively. Cyan spheres indicate water molecules. Green lines show Pi–Pi contacts.
Figure 6. Zoomed in view of an MAO-A binding pocket. Panels (a,b) reported the best pose returned from docking analysis for CH5 (green sticks) and CH4 (yellow sticks), respectively. Cyan spheres indicate water molecules. Green lines show Pi–Pi contacts.
Pharmaceutics 13 00850 g006
Pharmaceutics 13 00850 g007 550
Figure 7. Zoomed in view of an MAO-B binding pocket. Panels (a,b) reported the best pose returned from docking analysis for CH5 (green sticks) and CH4 (yellow sticks), respectively. Cyan spheres indicate water molecules. Green lines show Pi–Pi contacts.
Figure 7. Zoomed in view of an MAO-B binding pocket. Panels (a,b) reported the best pose returned from docking analysis for CH5 (green sticks) and CH4 (yellow sticks), respectively. Cyan spheres indicate water molecules. Green lines show Pi–Pi contacts.
Pharmaceutics 13 00850 g007
Pharmaceutics 13 00850 g008 550
Figure 8. Zoomed in view of a BACE-1 binding pocket. Panels (a,b) reported the best pose returned from docking analysis for CH5 (green sticks) and CH4 (yellow sticks), respectively.
Figure 8. Zoomed in view of a BACE-1 binding pocket. Panels (a,b) reported the best pose returned from docking analysis for CH5 (green sticks) and CH4 (yellow sticks), respectively.
Pharmaceutics 13 00850 g008
Pharmaceutics 13 00850 g009 550
Figure 9. Predicted pharmacokinetic profile of CH series.
Figure 9. Predicted pharmacokinetic profile of CH series.
Pharmaceutics 13 00850 g009
Table
Table 1. Inhibitions of MAO-A, MAO-B, AChE, BChE, and BACE-1 by halogenated trimethoxy chalcone derivatives a.
Table 1. Inhibitions of MAO-A, MAO-B, AChE, BChE, and BACE-1 by halogenated trimethoxy chalcone derivatives a.
CompoundsResidual Activity (%)IC50 (µM)SI b
MAO-AMAO-BAChEBChEBACE-1MAO-AMAO-BBACE-1
CH190.1 ± 7.5170.7 ± 2.1689.2 ± 2.2371.1 ± 0.6861.3 ± 0.078
CH292.4 ± 1.1084.3 ± 3.0083.8 ± 7.9674.5 ± 0.7157.2 ± 0.46
CH394.9 ± 7.1975.4 ± 0.2775.2 ± 3.4379.9 ± 0.7659.7 ± 0.077
CH463.7 ± 1.020.93 ± 0.2572.5 ± 7.2273.8 ± 0.7054.3 ± 2.2012.7 ± 0.230.84 ± 0.02513.6 ± 0.09415.1
CH566.7 ± 3.960.38 ± 0.5381.5 ± 5.3167.1 ± 0.6464.3 ± 0.7414.4 ± 1.100.46 ± 0.1219.8 ± 0.1231.3
CH692.1 ± 0.7519.6 ± 2.1783.2 ± 1.2384.6 ± 0.8066.7 ± 0.45 4.17 ± 0.23
Toloxatone 1.08 ± 0.025--
Lazabemide -0.11 ± 0.016-
Clorgyline 0.007 ± 0.0007--
Pargyline -0.14 ± 0.0059-
Quercetin --13.4 ± 0.035
a Results are the means ± standard errors of duplicate or triplicate experiments. b Selectivity index (SI) values are expressed for MAO-B as compared with MAO-A. IC50 values of donepezil for AChE and BChE were 0.0095 ± 0.0019 and 0.18 ± 0.0038 µM, respectively. Values for reference compounds were determined after preincubation with enzymes for 30 min.3.3. Kinetic Study.
Table
Table 2. BBB assay of the CH compounds.
Table 2. BBB assay of the CH compounds.
CompoundsBibliography
Pe (×10−6 cm/s) a		Experimental
Pe (×10−6 cm/s)		Prediction
Progesterone9.39.02 ± 0.11CNS+
Verapamil16.015.53 ± 0.24CNS+
Piroxicam2.52.43 ± 0.30CNS+/−
Lomefloxacin1.11.12 ± 0.01CNS−
Dopamine0.20.22 ± 0.01CNS−
CH1 13.22 ± 0.33CNS+
CH2 14.06 ± 0.80CNS+
CH3 15.33 ± 0.71CNS+
CH4 14.56 ± 0.26CNS+
CH5 15.65 ± 0.22CNS+
CH6 15.22 ± 0.26CNS+
CNS+ (high): Pe (10−6 cm/s) > 4.00; CNS− (low): Pe (10−6 cm/s) < 2.00; CNS± (uncertain): Pe (10−6 cm/s) from 4.00 to 2.00. a from [61].
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Vishal, P.K.; Oh, J.M.; Khames, A.; Abdelgawad, M.A.; Nair, A.S.; Nath, L.R.; Gambacorta, N.; Ciriaco, F.; Nicolotti, O.; Kim, H.; et al. Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders. Pharmaceutics 2021, 13, 850. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13060850

AMA Style

Vishal PK, Oh JM, Khames A, Abdelgawad MA, Nair AS, Nath LR, Gambacorta N, Ciriaco F, Nicolotti O, Kim H, et al. Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders. Pharmaceutics. 2021; 13(6):850. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13060850

Chicago/Turabian Style

Vishal, Payyalot Koyiparambath, Jong Min Oh, Ahmed Khames, Mohamed A. Abdelgawad, Aathira Sujathan Nair, Lekshmi R. Nath, Nicola Gambacorta, Fulvio Ciriaco, Orazio Nicolotti, Hoon Kim, and et al. 2021. "Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders" Pharmaceutics 13, no. 6: 850. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13060850

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop